The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...

Medically reviewed by Marla Anderson, MD Key Takeaways Triple-negative breast cancer is aggressive and often resists ...

DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...

A Purdue University team has discovered a new therapeutic target for triple-negative breast cancer. The research, led by Kyle ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

Strides in cancer research are happening in Dallas. Most recently, breast cancer doctors say they may have found a new way to fight one of the most devastating subtypes of cancer. UT Southwestern ...

Purdue researchers identify the PACT protein as a potential target for triple-negative breast cancer, opening new paths for future treatments.

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among ...